Jarrett M P, Santhanam S, Del Greco F
Arch Intern Med. 1983 Jul;143(7):1353-6.
Despite treatment advances, renal failure still develops in patients with systemic lupus erythematosus (SLE). With the common use of long-term maintenance hemodialysis, this complication is no longer fatal. In order to evaluate factors that contribute to the outcome of patients with SLE receiving long-term hemodialysis, we retrospectively analyzed the clinical course of 14 patients with SLE receiving hemodialysis for more than three months, and compared them with 62 patients receiving long-term hemodialysis who did not have SLE. While receiving long-term hemodialysis, SLE activity was minimal, with most manifestations involving the CNS or synovitis. Five-year survival was significantly lower in the SLE than in the non-SLE group (58.6% v 88.5%), but no deaths were directly attributable to SLE activity. Morbidity in the SLE group was primarily due to infection and vascular access problems.
尽管治疗取得了进展，但系统性红斑狼疮（SLE）患者仍会出现肾衰竭。随着长期维持性血液透析的普遍应用，这种并发症已不再致命。为了评估影响接受长期血液透析的SLE患者预后的因素，我们回顾性分析了14例接受血液透析超过三个月的SLE患者的临床病程，并将他们与62例接受长期血液透析但无SLE的患者进行比较。在接受长期血液透析期间，SLE活动度极小，大多数表现累及中枢神经系统或滑膜炎。SLE患者的五年生存率显著低于非SLE组（58.6%对88.5%），但没有死亡直接归因于SLE活动。SLE组的发病率主要归因于感染和血管通路问题。
